Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non‐small‐cell lung cancer
Alterations of the lower respiratory tract microbiome indicate different clinical responses to ICB within advanced NSCLC. Reduced microbial diversity of lower respiratory tracts impairs anti-tumoral performances. Microbe-derived metabolites perform as a dominant regulator to remodify the microecological environment in lower respiratory tracts. Multi-omics sequencings of the lower respiratory tract possess the potential to predict the long-term clinical responses to ICB among advanced NSCLC.
Authors
- Ke Wang (ORCID: https://orcid.org/0000-0001-8913-7115)
- Ning Chang (ORCID: https://orcid.org/0000-0003-2842-7658)
- Xiang‐Xiang Chen
- Zhi‐Nan Chen (ORCID: https://orcid.org/0000-0001-5512-4623)
- Pengyu Jing (ORCID: https://orcid.org/0000-0001-7378-4887)
- Qing Ju
- Yuan Wang (ORCID: https://orcid.org/0000-0002-6324-6134)
- Jian Zhang (ORCID: https://orcid.org/0000-0001-9877-1601)
- Yong Zhang (ORCID: https://orcid.org/0009-0009-2943-544X)
- Ling Li (ORCID: https://orcid.org/0000-0002-2763-0761)
- Dan Qiu (ORCID: https://orcid.org/0000-0002-6049-2858)
- Ruo Chen (ORCID: https://orcid.org/0000-0003-2578-8562)
- Min Wang (ORCID: https://orcid.org/0009-0009-9732-3570)
Institutions
- Xiangnan University (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Clinical and Translational Medicine
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1002/ctm2.70170
- Citations
- 9
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 9.41
Funders
- National Natural Science Foundation of China